Phase 4Recruiting

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits

Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits: a Randomized, Double-blind, Placebo-controlled Trial

Sponsor
VA Office of Research and Development (US federal)
Enrollment
226 planned
Conditions
Epilepsy
Interventions
Methylphenidate; Placebo; Methylphenidate
Ages
adults, older adults
Registry
NCT04419272

Full record on ClinicalTrials.gov

From the registry

Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy. In this study, participants will be assigned randomly (i.e., by flip of a coin), to a group that takes MPH and a group that takes a placebo (sugar pill). Participants will not know the group to which they have been assigned. Tests of attention and memory will be completed before taking the study pills and at Week 8. All participants will then have the option of taking MPH for the next two months, and attention and memory will be tested again at Week 16. The study will determine whether methylphenidate is helpful for the treatment of attention and memory problems in adults with epilepsy, and whether the medication is safe and beneficial when taken over an extended time period.

Primary outcomes

  • Change in Conners Continuous Performance Test (CPT), Following Placebo vs. Methylphenidate

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered